Display options
Cite
Bettiol A, Pregnolato F, Sciascia S, et al. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218377.
Bettiol, A., Pregnolato, F., Sciascia, S., Emmi, G., Prisco, D., & Meroni, P. L. (2020). Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218377
Bettiol, Alessandra, et al. "Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218377
Bettiol A, Pregnolato F, Sciascia S, Emmi G, Prisco D, Meroni PL. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218377. Epub 2020 Aug 04. PMID: 32753414.
Copy Download .nbib Format: NLM
Share it on

Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218377. Epub 2020 Aug 04.

Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou .

Annals of the rheumatic diseases

Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni

Affiliations

  1. Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Firenze, Italy.
  2. Experimental Laboratory of Immuno-rheumatology, Istituto Auxologico Italiano, IRCCS, Cusano Milanino, Italy.
  3. Dipartimento di Malattie Rare, Immunologiche, Ematologiche ed Immunoematologiche, Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare, Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale Torino Nord Emergenza San G. Bosco ed Università di Torino, Torino, Italy.
  4. Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy [email protected].
  5. Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy.

PMID: 32753414 DOI: 10.1136/annrheumdis-2020-218377

[No abstract available.]

Keywords: antibodies, antiphospholipid; biological therapy; cardiovascular diseases; hydroxychloroquine; lupus erythematosus, systemic

Conflict of interest statement

Competing interests: None declared.

Publication Types